靶向多发性骨髓瘤中的肿瘤干细胞。
Targeting cancer stem cells in multiple myeloma.
机构信息
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Los Angeles, CA 91010, USA; Toni Stephenson Lymphoma Center, City of Hope, Los Angeles, CA 91010, USA.
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
出版信息
Trends Cancer. 2024 Aug;10(8):733-748. doi: 10.1016/j.trecan.2024.06.002. Epub 2024 Jul 5.
Multiple myeloma (MM) is a hematological malignancy of bone marrow (BM) plasma cells with excessive clonal expansion and is associated with the overproduction of light-chain or monoclonal immunoglobulins (Igs). MM remains incurable, with high rates of relapses and refractory disease after first-line treatment. Cancer stem cells (CSCs) have been implicated in drug resistance in MM; however, the evidence for CSCs in MM is not adequate, partly due to a lack of uniformity in the definitions of multiple myeloma stem cells (MMSCs). We review advances in understanding MMSCs and their role in drug resistance to MM therapies. We also discuss novel therapeutic strategies to overcome MMSC-mediated relapses and drug resistance.
多发性骨髓瘤（MM）是骨髓（BM）浆细胞的血液系统恶性肿瘤，具有过度克隆性扩张，并与轻链或单克隆免疫球蛋白（Igs）的过度产生有关。MM 仍然无法治愈，一线治疗后复发和难治性疾病的发生率很高。癌症干细胞（CSC）与 MM 中的耐药性有关；然而，MM 中 CSC 的证据并不充分，部分原因是多发性骨髓瘤干细胞（MMSC）的定义缺乏一致性。我们回顾了对 MMSC 的理解及其在 MM 治疗耐药性中的作用的进展。我们还讨论了克服 MMSC 介导的复发和药物耐药性的新的治疗策略。
Zotero 插件